A temporary, full time position for a statistician is available at the NCPE. For more information click here.
Following NCPE assessment of the company submission, gemtuzumab ozogamicin (Mylotarg®) (with daunorubicin and cytarabine) is not considered cost effective for the treatment of patients ≥ 15 years with previously untreated, de novo CD33-positive acute myeloid leukaemia, except acute promyelocytic leukaemia, and therefore is not recommended for reimbursement at the submitted
The NCPE recommends that rivaroxaban + aspirin not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.